Jacob Bell

The French pharmaceutical giant said it’s in negotiations to sell a controlling stake of Opella to the private equity firm CD&R, in a deal that reportedly could be worth more than $16 billion.

The deal would hand Lundbeck a treatment for a series of rare brain disorders that could, by the company's estimates, become a blockbuster product.

AbbVie has pitched the drug, now called Vyalev, as a potential blockbuster product and a much-needed option for patients with advanced disease.

Shares in the Boston-based biotech creator, which had a standout success in forming Karuna Therapeutics, trade around cash levels — a “huge value disconnect” its leaders are trying to bridge.

Launched by PureTech and backed by well-known venture capital firms, the startup has raised $325 million since its debut this spring.

While analysts still see value in Alto’s approach to brain drugmaking, investors may have lost some faith, as the biotech’s shares were down by two-thirds Wednesday morning.

Buying Aliada Therapeutics would hand AbbVie a clinical-stage Alzheimer’s medicine and a drugmaking technology that may be useful for a variety of brain diseases.

Even though Biogen raised earnings guidance, the company still has “some potentially concerning signals” in its base business, according to one analyst.

The funding for Axonis, which is developing novel medicines for pain and epilepsy, reflects growing confidence in precision therapies for neurological diseases, one investor told BioPharma Dive.

The Office of the U.S. Trade Representative (USTR) has opened a process whereby parties can request exclusions from Section 301 tariffs for imports of...